Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.
M Vaz BatistaJ M Pérez-GarcíaP CortezL GarrigósM Fernández-AbadM GionA Martínez-BuenoC SaavedraI TeruelA Fernandez-OrtegaS ServitjaM Ruiz-BorregoJ de la Haba-RodríguezG MartratJ Pérez-EscuredoD Alcalá-LópezM Sampayo-CorderoS BragaJ CortésA Llombart-CussacPublished in: ESMO open (2024)
T-DXd demonstrated promising intracranial activity in pretreated HER2-low ABC patients with active BMs. Further studies are needed to validate these results in larger cohorts. This trial is registered with ClinicalTrials.gov, NCT04420598.